Small molecule degraders of the hepatitis C virus protease reduce susceptibility to resistance mutations

Targeted protein degradation is a promising drug development paradigm. Here we leverage this strategy to develop a new class of small molecule antivirals that induce proteasomal degradation of viral proteins. Telaprevir, a reversible-covalent inhibitor that binds to the hepatitis C virus (HCV) prote...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Nat Commun
Main Authors: de Wispelaere, Mélissanne, Du, Guangyan, Donovan, Katherine A., Zhang, Tinghu, Eleuteri, Nicholas A., Yuan, Jingting C., Kalabathula, Joann, Nowak, Radosław P., Fischer, Eric S., Gray, Nathanael S., Yang, Priscilla L.
Formato: Artigo
Idioma:Inglês
Publicado: Nature Publishing Group UK 2019
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6672008/
https://ncbi.nlm.nih.gov/pubmed/31371704
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41467-019-11429-w
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares